Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.0111
Handel nachbörslich:
.01
0.01
+
Schlusskurs vom Vortag:
$0.0111
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
$547.00K
Nettoeinkommen (Verlust:
$-34.02M
KGV:
0.00
EPS:
-46.9127
Netto-Cashflow:
$-27.11M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$1.14
Trevena Inc Stock (TRVN) Company Profile
Compare TRVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVN
Trevena Inc
|
0.00 | 0 | 547.00K | -34.02M | -27.11M | -46.91 |
VRTX
Vertex Pharmaceuticals Inc
|
445.04 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.48 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
898.94 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.39 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Trevena Inc Stock (TRVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-15 | Eingeleitet | Oppenheimer | Perform |
| 2020-09-14 | Eingeleitet | Guggenheim | Buy |
| 2020-08-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-05-31 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-11-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-10-12 | Herabstufung | Needham | Buy → Hold |
| 2018-10-10 | Herabstufung | Jefferies | Buy → Hold |
| 2017-11-08 | Bestätigt | Needham | Buy |
| 2017-10-16 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2017-10-12 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-08 | Bestätigt | Needham | Buy |
| 2017-02-23 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-22 | Bestätigt | FBR & Co. | Outperform |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2016-05-17 | Bestätigt | FBR Capital | Outperform |
| 2016-05-17 | Bestätigt | Needham | Buy |
| 2016-03-29 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-01 | Bestätigt | Wedbush | Outperform |
| 2015-08-03 | Eingeleitet | Brean Capital | Buy |
Alle ansehen
Trevena Inc Aktie (TRVN) Neueste Nachrichten
Diabetic Peripheral Neuropathy Pipeline Accelerates as 15+ - openPR.com
Opioids Market Size, Share, Growth, Analysis, Report, 2034 - Straits Research
Trevena Inc stock (US89365K1007): low-priced biotech name draws speculative interest despite limited - AD HOC NEWS
Europe Stocks: Research Stocks from Europe Stock Market - GuruFocus
Number of shareholders of Trevena, Inc. – OTC:TRVN - TradingView
Trevena Inc stock (US89365K1007): biotech minnow fights for time after Nasdaq delisting and restruct - AD HOC NEWS
Number of shareholders of Trevena, Inc. – MUN:6T4 - TradingView
Trevena stock (US89365K1007): pipeline setbacks, Nasdaq pressure and what investors should know now - AD HOC NEWS
Trevena Inc stock (US89365K1007): Trading at $0.011 amid biopharma challenges - AD HOC NEWS
Catalent, Inc. Common Stock (NY: CTLT - FinancialContent
Trevena Inc (TRVN) Stock Price & 30 Year Financial Data - GuruFocus
Trevena Inc (TRVN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Trevena Inc (OTCM:TRVN) Stock Earnings Transcripts - GuruFocus
Trevena Inc (OTCM:TRVN) Dividend - GuruFocus
Trevena Inc (OTCM:TRVN) SEC filings - GuruFocus
Trevena Inc (OTCM:TRVN) Insider Trading Activity | Apple Insider Buys and Sells - GuruFocus
Trevena Inc stock (US89365K1007): Biopharma firm focuses on pain and CNS pipeline amid cash burn con - AD HOC NEWS
Health News Round upopioid pain drugs, Ebola vaccinations in Uganda and much mmore - Devdiscourse
Diabetic Neuropathy Pipeline Set for Significant - openPR.com
Diabetic Neuropathy Pipeline Set for Significant Breakthroughs by 2026 with 20+ Therapies and Robust Clinical Advancements | DelveInsight - Barchart.com
Polaris Venture Partners V L P Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Verastem, Inc. (VSTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight - Barchart.com
TherapeuticsMD, Inc. (TXMD) stock price, news, quote and history - Yahoo Finance UK
Trevena (STU:6T4) PB Ratio : (As of Mar. 28, 2026) - gurufocus.com
Stock List: Research Stocks from Around the World - GuruFocus
SMX (Security Matters) Public Limited CompanyOrdinary Shares (NQ: SMX - The Chronicle-Journal
Wall Street closes lower, as war on Iran fuels inflation worries - marketscreener.com
S&P Closes Out Third Straight Week of Loses | Closing Bell - marketscreener.com
US Stocks Brief: S&P Futures Down 0.25% - marketscreener.com
Elon Musk's SpaceX weighs Nasdaq listing, sources say - marketscreener.com
Celebrity-studded Caliwater bets cactus is next big wave in hydration - Food Dive
Wall Street opens lower as investors weigh Middle East war risks - marketscreener.com
TRVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Trump Says Stock Market Hit 53 New Highs on His Watch - marketscreener.com
US software stocks climb as Anthropic announcement sparks relief rally - marketscreener.com
VINC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
U.S. S&P 500 E-mini and Nasdaq 100 futures flat, Dow futures down 0.1% - marketscreener.com
Wall Street ends higher, lifted by Nvidia and other AI stocks - marketscreener.com
Tg-17 Inc changes corporate name to Our Bond, Inc. - marketscreener.com
Coinshares Updates on Fourth Quarter, Plans $0.33 Dividend Per Share - marketscreener.com
Investor Increases its Stake in Nasdaq - marketscreener.com
Why Arcadium Lithium Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Novakand Pharma applies for Nasdaq's approval of continued listing - marketscreener.com
S&P 500, Nasdaq turn negative; S&P down 0.4%, Nasdaq falls 0.9% - marketscreener.com
Braiin Shares to Begin Trading on Nasdaq - marketscreener.com
Columbus Circle Capital Corp II Prices $200 Million Initial Public Offering - marketscreener.com
Sanofi Concludes $2.2 Billion Takeover of Dynavax Technologies - marketscreener.com
Spring Valley Acquisition Corp. IV Prices $200 Million IPO - marketscreener.com
Caliwater hires first CEO - Food Business News
Unique Global Innovative Solutions Corp. (Ugiz) announces intent to pursue Nasdaq uplisting and capital raise - marketscreener.com
Finanzdaten der Trevena Inc-Aktie (TRVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.65%
1.27%
Kapitalisierung:
|
Volumen (24h):